Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: A comparative study of 67 cases

Yang Shi, Andrew J. Rand, Jennifer H. Crow, Joseph O. Moore, Anand S. Lagoo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: To compare the features of the blast phase of chronic myelogenous leukemia (CML) in patients treated with tyrosine kinase inhibitors (TKIs) with those in the pre-TKI era. Methods: Sixty-seven patients with blast phase CML were identified in the Duke Pathology database from 1991 to 2011. The morphology and immunophenotype of blasts were evaluated, along with cytogenetic studies and associated findings in the peripheral blood and bone marrow. Results: In the TKI era, the blasts were more frequently of a type other than the usual myeloid or lymphoid types when compared with the pre-TKI era. Blast phase in TKI-treated patients was associated with a higher peripheral WBC count and a lower blast percentage in the bone marrow. Of the 23 patients with cytogenetic studies during blast phase, additional cytogenetic changes more frequently occurred in patients with an unusual blast type, and some patients showed these changes months before the onset of blast phase. Conclusions: Blast phase CML in TKI- and non-TKI-treated patients differs in the morphology and immunophenotype of blasts, cytogenetic findings, and associated findings in the peripheral blood and bone marrow.

Original languageEnglish (US)
Pages (from-to)105-119
Number of pages15
JournalAmerican Journal of Clinical Pathology
Volume143
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Cytogenetics
Bone Marrow
Phosphotransferases
Databases
Pathology

Keywords

  • Blast phase
  • Chronic myelogenous leukemia
  • Cytogenetics
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors : A comparative study of 67 cases. / Shi, Yang; Rand, Andrew J.; Crow, Jennifer H.; Moore, Joseph O.; Lagoo, Anand S.

In: American Journal of Clinical Pathology, Vol. 143, No. 1, 01.01.2015, p. 105-119.

Research output: Contribution to journalArticle

@article{14c6b1f6d357400998d9c7d65208816f,
title = "Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: A comparative study of 67 cases",
abstract = "Objectives: To compare the features of the blast phase of chronic myelogenous leukemia (CML) in patients treated with tyrosine kinase inhibitors (TKIs) with those in the pre-TKI era. Methods: Sixty-seven patients with blast phase CML were identified in the Duke Pathology database from 1991 to 2011. The morphology and immunophenotype of blasts were evaluated, along with cytogenetic studies and associated findings in the peripheral blood and bone marrow. Results: In the TKI era, the blasts were more frequently of a type other than the usual myeloid or lymphoid types when compared with the pre-TKI era. Blast phase in TKI-treated patients was associated with a higher peripheral WBC count and a lower blast percentage in the bone marrow. Of the 23 patients with cytogenetic studies during blast phase, additional cytogenetic changes more frequently occurred in patients with an unusual blast type, and some patients showed these changes months before the onset of blast phase. Conclusions: Blast phase CML in TKI- and non-TKI-treated patients differs in the morphology and immunophenotype of blasts, cytogenetic findings, and associated findings in the peripheral blood and bone marrow.",
keywords = "Blast phase, Chronic myelogenous leukemia, Cytogenetics, Tyrosine kinase inhibitor",
author = "Yang Shi and Rand, {Andrew J.} and Crow, {Jennifer H.} and Moore, {Joseph O.} and Lagoo, {Anand S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1309/AJCPWEX5YY4PHSCN",
language = "English (US)",
volume = "143",
pages = "105--119",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors

T2 - A comparative study of 67 cases

AU - Shi, Yang

AU - Rand, Andrew J.

AU - Crow, Jennifer H.

AU - Moore, Joseph O.

AU - Lagoo, Anand S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: To compare the features of the blast phase of chronic myelogenous leukemia (CML) in patients treated with tyrosine kinase inhibitors (TKIs) with those in the pre-TKI era. Methods: Sixty-seven patients with blast phase CML were identified in the Duke Pathology database from 1991 to 2011. The morphology and immunophenotype of blasts were evaluated, along with cytogenetic studies and associated findings in the peripheral blood and bone marrow. Results: In the TKI era, the blasts were more frequently of a type other than the usual myeloid or lymphoid types when compared with the pre-TKI era. Blast phase in TKI-treated patients was associated with a higher peripheral WBC count and a lower blast percentage in the bone marrow. Of the 23 patients with cytogenetic studies during blast phase, additional cytogenetic changes more frequently occurred in patients with an unusual blast type, and some patients showed these changes months before the onset of blast phase. Conclusions: Blast phase CML in TKI- and non-TKI-treated patients differs in the morphology and immunophenotype of blasts, cytogenetic findings, and associated findings in the peripheral blood and bone marrow.

AB - Objectives: To compare the features of the blast phase of chronic myelogenous leukemia (CML) in patients treated with tyrosine kinase inhibitors (TKIs) with those in the pre-TKI era. Methods: Sixty-seven patients with blast phase CML were identified in the Duke Pathology database from 1991 to 2011. The morphology and immunophenotype of blasts were evaluated, along with cytogenetic studies and associated findings in the peripheral blood and bone marrow. Results: In the TKI era, the blasts were more frequently of a type other than the usual myeloid or lymphoid types when compared with the pre-TKI era. Blast phase in TKI-treated patients was associated with a higher peripheral WBC count and a lower blast percentage in the bone marrow. Of the 23 patients with cytogenetic studies during blast phase, additional cytogenetic changes more frequently occurred in patients with an unusual blast type, and some patients showed these changes months before the onset of blast phase. Conclusions: Blast phase CML in TKI- and non-TKI-treated patients differs in the morphology and immunophenotype of blasts, cytogenetic findings, and associated findings in the peripheral blood and bone marrow.

KW - Blast phase

KW - Chronic myelogenous leukemia

KW - Cytogenetics

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84923568687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923568687&partnerID=8YFLogxK

U2 - 10.1309/AJCPWEX5YY4PHSCN

DO - 10.1309/AJCPWEX5YY4PHSCN

M3 - Article

C2 - 25511149

AN - SCOPUS:84923568687

VL - 143

SP - 105

EP - 119

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -